Sammlung aktueller Literatur zum Thema

"Medizin rund um das Herz"

Neu! 

AT I Blocker

Losartan

Renaal Studie

Irbesartan

Progression der Niereninsuffizienz(IDNT)

Entwicklung einer Mikroalbuminurie (IRMA 2)

Antithrombotika

Clopidogrel

Clopidogrel bei instabiler Angina pectoris (Cure Studie)

Intensivtherapie

Dopamin

Dopamin bei akutem Nierenversagen

Cox 2 Hemmer

Gefahr von kardiovasculären Nebenwirkungen

  Interaktion mit Aspirin

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. Neu! 

Östrogensubstitution in der Menopause

  A clinical trial of estrogen-replacement therapy after ischemic stroke. Neu! 

 

Invasive Therapie

A Trial of invasive versus medical therapy in elderly patients: TIME Neu! 

 

 


Titel:

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Autoren:

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK

Literaturstelle:

N Engl J Med 2001 Aug 16;345(7):494-502

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=N+Engl+J+Med[jour]+AND+345[volume]+AND+494[page]+AND+2001[pdat]

Schlußfolgerungen der Autoren:

The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.


Titel:

Risk of cardiovascular events associated with selective COX-2 inhibitors.

Autoren:

Mukherjee D, Nissen SE, Topol EJ.

Literaturstelle:

JAMA 2001 Aug 22-29;286(8):954-9

Internet-Adresse für Abstract:

 http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=JAMA[jour]+AND+286[volume]+AND+954[page]+AND+2001[pdat

Schlußfolgerungen der Autoren:

The available data raise a cautionary flag about the risk of

cardiovascular events with COX-2 inhibitors. Further prospective trial

evaluation may characterize and determine the magnitude of the risk.

Weitere Informationen:

1 FDA Advisory Committee. Cardiovascular safety review of Rofecoxib:

http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf

 

6 FDA CLASS Advisory Committee. CLASS Advisory Committee Briefing Document:

http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_01_searle.pdf

 


Titel:

Use of dopamine in acute renal failure: a meta-analysis.

Autoren:

Kellum JA, M Decker J.

Literaturstelle:

Crit Care Med 2001 Aug;29(8):1526-31

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=Crit+Care+Med[jour]+AND+1526[page]+AND+2001[pdat]

Schlußfolgerungen der Autoren:

The use of low-dose dopamine for the

treatment or prevention of acute renal failure cannot be justified on the basis

of available evidence and should be eliminated from routine clinical use.

Publication Types:

 


Titel:

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Autoren:

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC,

Rohde R, Raz I; Collaborative Study Group.

Literaturstelle:

1: N Engl J Med 2001 Sep 20;345(12):851-60

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=N+Engl+J+Med[jour]+AND+345[volume]+AND+851[page]+AND+2001[pdat

Schlußfolgerungen der Autoren:

The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes.

Acronym: IDNT


Titel:

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Autoren:

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G,

Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

Literaturstelle:

N Engl J Med 2001 Sep 20;345(12):861-9

Comment in:

N Engl J Med. 2001 Sep 20;345(12):910-2. UI: 21429791

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=N+Engl+J+Med[jour]+AND+345[volume]+AND+861[page]+AND+2001[pdat

Schlußfolgerungen der Autoren:

Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally

well tolerated.

 


Titel:

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Autoren:

Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P;

Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

Literaturstelle:

1: N Engl J Med 2001 Sep 20;345(12):870-8

Comment in:

N Engl J Med. 2001 Sep 20;345(12):910-2. UI: 21429791

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?orig_db=PubMed&db=PubMed&cmd=Search&defaultField=Title+Word&term=N+Engl+J+Med[jour]+AND+345[volume]+AND+870[page]+AND+2001[pdat

Schlußfolgerungen der Autoren:

Irbesartan is renoprotective independently of ist blood-pressure-lowering effect in patients with type 2 diabetes and

microalbuminuria.

Acronym: IRMA 2


Titel:

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Autoren:

Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B,

Vyas SN, FitzGerald GA.

Literaturstelle:

1: N Engl J Med 2001 Dec 20;345(25):1809-17

Comment in:

N Engl J Med. 2001 Dec 20;345(25):1844-6.

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11752357&dopt=Abstract

Schlußfolgerungen der Autoren:

The concomitant

administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac

antagonizes the irreversible platelet inhibition induced by aspirin. Treatment

with ibuprofen in patients with increased cardiovascular risk may limit the

cardioprotective effects of aspirin.

Mein Kommentar:

Acronym:

 


Titel:

A clinical trial of estrogen-replacement therapy after ischemic stroke.

Autoren:

Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI.

 

Literaturstelle:

N Engl J Med 2001 Oct 25;345(17):1243-9

 

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11680444&dopt=Abstract

Schlußfolgerungen der Autoren:

Estradiol does not reduce mortality or the recurrence of stroke in postmenopausal women with cerebrovascular disease. This therapy should not be prescribed for the secondary prevention of cerebrovascular disease.

 

Mein Kommentar:


Titel:

Trial of invasive versus medical therapy in elderly patients with chronic

symptomatic coronary-artery disease (TIME): a randomised trial.

Autoren:

The TIME Investigators.

Literaturstelle:

Lancet 2001 Sep 22;358(9286):951-7

Comment in: Lancet. 2001 Sep 22;358(9286):945-6.

Internet-Adresse für Abstract:

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11583747&dopt=Abstract

http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11583742

Schlußfolgerungen der Autoren:

Patients aged 75 years or older with

angina despite standard drug therapy benefit more from revascularisation than

from optimised medical therapy in terms of symptom relief and quality of life.

Therefore, these patients should be offered invasive assessment despite their

high risk profile followed by revascularisation if feasible.

 

Mein Kommentar:

Acronym:

TIME